Fighting against rare diseases together
Diseases that are rare, need much more care
Rare diseases are serious, chronic, debilitating and life-threatening diseases that require long-term and specialized management. These rare diseases disproportionately impact children, often resulting in some form of handicap, which can sometimes be extremely severe. Given their rarity, these conditions are difficult to diagnose and treat. Patients end up enduring a long journey involving specialty doctors, tests and misdiagnoses.
Around 7,000 rare diseases exist impacting ~300 million people worldwide1
The Organization for Rare Diseases India (ORDI) has currently listed 264 rare diseases in India, while an approximate figure of around 70 million individuals in the Indian population can be estimated to be living with such rare disorders.2
Rare diseases do not discriminate; they affect people from all walks of life and in all economic circumstances.
In support of people with rare diseases: Indian Charitable Access Program
For patients with rare diseases, we are committed to not only develop effective therapies but also ensure that these therapies reach them.
Since 1999, Sanofi's India Charitable Access Program (InCAP) has provided support to more than 100 patients in the country and continue to do so. The program is guided by an expert medical committee that remains closely involved in participating patients' care and progress.
25-years of Sanofi's presence for Rare Diseases in India
Our rare diseases business focuses on these uncommon and underserved medical conditions. We are committed to empowering the lives of patients with rare diseases by offering sustainable and transformative healthcare options.
Free Diagnostic Support
Since 2013, Sanofi has been offering diagnostic support for 5 Lysosomal Storage Disorders (LSDs) – Gaucher disease, Fabry disease, Pompe disease, MPS I, and ASMD. Over the last decade, we have enabled more than 10,000 tests under our diagnostic program.
Centres of Excellence
Centres of Excellence across India under National Policy on Rare Diseases (NPRD)3
References
MAT-IN-2501046-1.0-09/2025